Metastases to the breast from non-mammary sites are rare and pose a diagnostic and therapeutic challenge. They can be mistaken for primary breast malignancy, which is much more common. In this case report we describe the clinical, radiological and pathological features of a patient who developed breast metastases from an adrenocorticotropic hormone (ACTH) secreting thymic neuro-endocrine carcinoma. Patient was initially felt to have a primary breast malignancy, however, after further ancillary testing a diagnosis of metastatic thymic neuro-endocrine tumor was made.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/BD-130354 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of liquiritin on neuroendocrine-immune network in menopausal rat model.
Phytother Res
October 2020
Tang Center of Herbal Medicine Research and Department of Anesthesia and Critical Care, University of Chicago, Chicago, Illinois, USA.
Purpose: The aim of the study was to investigate the effect of liquiritin on neuroendocrine-immune network in menopausal rat model.
Methods: Liquiritin groups were respectively given liquiritin suspension at the dose of 80, 40, and 20 mg/kg, once a day for continuous 30 days after the removal of bilateral ovaries to induce the menopausal rat model. Behavioral experiments were conducted and the organs were weighed for the viscera index.
Prolonged response to Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor.
Invest New Drugs
August 2020
Department of Nuclear Medicine, Cochin Hospital, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.
Thymic neuro endocrine tumor (tNET) are extremely rare malignancies with poor prognosis, requiring investigation of novel therapeutic approaches. Lu-DOTATATE is a successful systemic treatment modality in patients with metastatic gastroenteropancreatic but it role in tNET is not yet well established. Here we report a case of a 39-year-old man with refractory bone marrow infiltration of a tNET, treated by 4 cycles of peptide receptor radionuclide therapy (PRRT) with Lu DOTATATE.
View Article and Find Full Text PDFThe future: surgical advances in MEN1 therapeutic approaches and management strategies.
Endocr Relat Cancer
October 2017
Thoracic and Endocrine Surgery and Faculty of MedicineUniversity Hospitals of Geneva, Geneva, Switzerland
Multiple endocrine neoplasia type 1 (MEN1) is a hereditary autosomal dominant disorder associated with numerous neuroendocrine tumors (NETs). Recent advances in the management of MEN1 have led to a decrease in mortality due to excess hormones; however, they have also led to an increase in mortality from malignancy, particularly NETs. The main challenges are to localize these tumors, to select those that need therapy because of the risk of aggressive behavior and to select the appropriate therapy associated with minimal morbidity.
View Article and Find Full Text PDFFriend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging.
Oncotarget
January 2017
Institute of Molecular Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA.
The interaction between T cells and the central nervous system (CNS) in homeostasis and injury has been recognized being both pathogenic (CD4+ T-helper 1 - Th1, Th17 and γδT) and ameliorative (Th2 and regulatory T cells - Tregs). However, in-depth studies aimed to elucidate the precise in the aged microenvironment and the dichotomous role of Tregs have just begun and many aspects remain unclear. This is due, not only to a mutual dependency and reciprocal causation of alterations and diseases between the nervous and T cell immune systems, but also to an inconsistent aging of the two systems, which dynamically changes with CNS injury/recovery and/or aging process.
View Article and Find Full Text PDFMEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines.
J Clin Endocrinol Metab
April 2015
Centre Hospitalier Universitaire de Dijon (P.G.), Endocrine Surgery, Dijon, France; INSERM U866, Dijon, France; University of Burgundy, Dijon, France; Service d'Endocrinologie et Maladies Métaboliques (A.D., N.L-B.), Centre Hospitalier Universitaire, Hôpital Robert Debré, Reims, France, Clinique d'Endocrinologie (M.L.), Centre Hospitalier Universitaire, Nantes, France; Service de Médecine Interne et Endocrinologie (C.C-B.), Clinique Marc Linquette, Centre Hospitalier Régional et Universitaire, Lille, France; Service d'Oncologie Médicale (P.N.), Institut Paoli-Calmettes, APHM, Université Aix-Marseille, Marseille, France; Service d'Endocrinologie (H.dB.), Centre Hospitalier de Chambéry, Chambéry, France; Département d'Endocrinologie (X.B.), Hôpital Cochin, Université Paris Descartes, Paris, France; Service de Gastroentérologie-Pancréatologie (P.R.), APHP, Hôpital Beaujon et Université Paris 7 Denis Diderot, Clichy, France; Fédération d'Endocrinologie (F.B-C.), Hospice Civils de Lyon et Université Lyon 1, Groupement Hospitalier Est. Lyon, France; Service d'Endocrinologie (B.V.), Diabète et Maladies Métaboliques, Centre Hospitalier Universitaire de Dijon, Hôpital du Bocage, Dijon, France; Département d'Endocrinologie (J.L.S.), Hopital de l'Archet, Nice, France; Service de Chirurgie Générale (F.M.), Viscérale et Endocrinienne, Groupement Hospitalier Universitaire Est, Hôpital de la Pitié, Paris, France; Service d'Endocrinologie (A.T.), Centre Hospitalier Universitaire, Hôpital du Haut Levêque, Pessac, France; Département d'Endocrinologie (J.M.K.), Hôpital Universitaire de Rouen. Rouen, France; Service d'Endocrinologie (P.dA.), Centre Hospitalier d'Avignon, Avignon, France; Service d'Endocrinologie (O.C.), Diabète et Maladies Métaboliques, Centre Hospitalier Universitaire de Grenoble, Hôpital Michalon, Grenoble, France; Service d'Endocrinologie (S.C-M.), Centre Hôpitalier Universitaire. Hôpital St-Antoine, Paris, France; Service d'Hép
Context: Multiple endocrine neoplasia Type-1 (MEN1) in young patients is only described by case reports.
Objective: To improve the knowledge of MEN1 natural history before 21 years old.
Methods: Obtain a description of the first symptoms occurring before 21 years old (clinical symptoms, biological or imaging abnormalities), surgical outcomes related to MEN1 Neuro Endocrine Tumors (NETs) occurring in a group of 160 patients extracted from the "Groupe d'étude des Tumeurs Endocrines" MEN1 cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!